BACKGROUND: Dementia is the most common cause of functional decline among elderly people and is associated with high costs of national healthcare in European countries. With increasing functional and cognitive decline, it is likely that many people suffering from dementia will receive institutional care in their lifetime. To delay entry to institutional care, many European countries invest in home and community based care services. OBJECTIVES: This study aimed to compare costs for people with dementia (PwD) at risk for institutionalization receiving professional home care (HC) with cost for PwD recently admitted to institutional long-term nursing care (ILTC) in eight European countries. Special emphasis was placed on differences in cost patterns across settings and countries, on the main predictors of costs and on a comprehensive assessment of costs from a societal perspective. METHODS: Interviews using structured questionnaires were conducted with 2,014 people with dementia and their primary informal caregivers living at home or in an ILTC facility. Costs of care were assessed with the resource utilization in dementia instrument. Dementia severity was measured with the standardized mini mental state examination. ADL dependence was assessed using the Katz index, neuropsychiatric symptoms using the neuropsychiatric inventory (NPI) and comorbidities using the Charlson. Descriptive analysis and multivariate regression models were used to estimate mean costs in both settings. A log link generalized linear model assuming gamma distributed costs was applied to identify the most important cost drivers of dementia care. RESULTS: In all countries costs for PwD in the HC setting were significantly lower in comparison to ILTC costs. On average ILTC costs amounted to 4,491 Euro per month and were 1.8 fold higher than HC costs (2,491 Euro). The relation of costs between settings ranged from 2.4 (Sweden) to 1.4 (UK). Costs in the ILTC setting were dominated by nursing home costs (on average 94%). In the HC setting, informal care giving was the most important cost contributor (on average 52%). In all countries costs in the HC setting increased strongly with disease severity. The most important predictor of cost was ADL independence in all countries, except Spain and France where NPI severity was the most important cost driver. A standard deviation increase in ADL independence translated on average into a cost decrease of about 22%. CONCLUSION: Transition into ILTC seems to increase total costs of dementia care from a societal perspective. The prevention of long-term care placement might be cost reducing for European health systems. However, this conclusion depends on the country, on the valuation method for informal caregiving and on the degree of impairment.
BACKGROUND:Dementia is the most common cause of functional decline among elderly people and is associated with high costs of national healthcare in European countries. With increasing functional and cognitive decline, it is likely that many people suffering from dementia will receive institutional care in their lifetime. To delay entry to institutional care, many European countries invest in home and community based care services. OBJECTIVES: This study aimed to compare costs for people with dementia (PwD) at risk for institutionalization receiving professional home care (HC) with cost for PwD recently admitted to institutional long-term nursing care (ILTC) in eight European countries. Special emphasis was placed on differences in cost patterns across settings and countries, on the main predictors of costs and on a comprehensive assessment of costs from a societal perspective. METHODS: Interviews using structured questionnaires were conducted with 2,014 people with dementia and their primary informal caregivers living at home or in an ILTC facility. Costs of care were assessed with the resource utilization in dementia instrument. Dementia severity was measured with the standardized mini mental state examination. ADL dependence was assessed using the Katz index, neuropsychiatric symptoms using the neuropsychiatric inventory (NPI) and comorbidities using the Charlson. Descriptive analysis and multivariate regression models were used to estimate mean costs in both settings. A log link generalized linear model assuming gamma distributed costs was applied to identify the most important cost drivers of dementia care. RESULTS: In all countries costs for PwD in the HC setting were significantly lower in comparison to ILTC costs. On average ILTC costs amounted to 4,491 Euro per month and were 1.8 fold higher than HC costs (2,491 Euro). The relation of costs between settings ranged from 2.4 (Sweden) to 1.4 (UK). Costs in the ILTC setting were dominated by nursing home costs (on average 94%). In the HC setting, informal care giving was the most important cost contributor (on average 52%). In all countries costs in the HC setting increased strongly with disease severity. The most important predictor of cost was ADL independence in all countries, except Spain and France where NPI severity was the most important cost driver. A standard deviation increase in ADL independence translated on average into a cost decrease of about 22%. CONCLUSION: Transition into ILTC seems to increase total costs of dementia care from a societal perspective. The prevention of long-term care placement might be cost reducing for European health systems. However, this conclusion depends on the country, on the valuation method for informal caregiving and on the degree of impairment.
Authors: A Gustavsson; L Jonsson; T Rapp; E Reynish; P J Ousset; S Andrieu; C Cantet; B Winblad; B Vellas; A Wimo Journal: J Nutr Health Aging Date: 2010-10 Impact factor: 4.075
Authors: Claudine de Meijer; Werner Brouwer; Marc Koopmanschap; Bernard van den Berg; Job van Exel Journal: Health Econ Date: 2010-07 Impact factor: 3.046
Authors: Howard H Feldman; Tuula Pirttila; Jean François Dartigues; Brian Everitt; Bart Van Baelen; Susanne Schwalen; Shane Kavanagh Journal: Int J Geriatr Psychiatry Date: 2009-05 Impact factor: 3.485
Authors: Thomas Rapp; Sandrine Andrieu; Laurent Molinier; Alain Grand; Christelle Cantet; C Daniel Mullins; Bruno Vellas Journal: Value Health Date: 2012-04-10 Impact factor: 5.725
Authors: Hilde Verbeek; Gabriele Meyer; Helena Leino-Kilpi; Adelaida Zabalegui; Ingalill Rahm Hallberg; Kai Saks; Maria Eugenia Soto; David Challis; Dirk Sauerland; Jan P H Hamers Journal: BMC Public Health Date: 2012-01-23 Impact factor: 3.295
Authors: Megan Shepherd-Banigan; Hailey J James; Valerie A Smith; Brenda L Plassman; Eric Jutkowitz; Emmanuelle Belanger; Courtney H Van Houtven Journal: J Appl Gerontol Date: 2020-02-06
Authors: Juan Oliva-Moreno; Marta Trapero-Bertran; Luz Maria Peña-Longobardo; Raúl Del Pozo-Rubio Journal: Pharmacoeconomics Date: 2017-03 Impact factor: 4.981
Authors: Anja Broda; Ansgar Wübker; Patrick Bremer; Gabriele Meyer; Anna Renom Guiteras; Dirk Sauerland; Astrid Stephan Journal: Z Gerontol Geriatr Date: 2019-02-15 Impact factor: 1.281
Authors: Philip Charles Gerard Klein; Simone Huygens; Ron Handels; Valérie Wester; Tim Andre Kanters Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Rebecca Palm; Saskia Jünger; Sven Reuther; Christian G G Schwab; Martin N Dichter; Bernhard Holle; Margareta Halek Journal: BMC Geriatr Date: 2016-04-05 Impact factor: 3.921
Authors: Martin Knapp; Kia-Chong Chua; Matthew Broadbent; Chin-Kuo Chang; Jose-Luis Fernandez; Dominique Milea; Renee Romeo; Simon Lovestone; Michael Spencer; Gwilym Thompson; Robert Stewart; Richard D Hayes Journal: BMJ Open Date: 2016-11-18 Impact factor: 2.692
Authors: Malin Degerman Gunnarsson; Martin Ingelsson; Kaj Blennow; Hans Basun; Lars Lannfelt; Lena Kilander Journal: Alzheimers Res Ther Date: 2016-06-06 Impact factor: 6.982